Same drug. New shape. Big difference for patients.
China's NMPA just approved a tablet version of selpercatinib (Retevmo) — the world's first highly selective RET inhibitor with CNS activity — expanding on its 2022 capsule approval. 🧪
@dengyuemedicine.bsky.social